Bicara Therapeutics Schedule 13G/A shows Deep Track-related reporting persons beneficially own 4,062,500 shares of common stock, representing 6.21% of the class. The filing states 65,467,187 shares outstanding as of March 24, 2026 (issuer 10-K). The ownership is reported as shared voting and dispositive power and is reported by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin.
Positive
None.
Negative
None.
Insights
Large passive stake disclosed: shared control of 4,062,500 shares (6.21%).
Deep Track entities and David Kroin report beneficial ownership of 4,062,500 shares, based on 65,467,187 shares outstanding as of March 24, 2026. The filing classifies the position as shared voting and dispositive power.
Holdings are reported via a joint filing; cash‑flow treatment or intent (active trading, control change) is not stated in the excerpt. Subsequent filings would show material changes in position.
Joint filing signals coordinated reporting, with David Kroin shown as control person for the fund entity.
The statement includes a joint filing clause and identifies Deep Track Capital, LP as the relevant entity for which David Kroin may be a control person. Signatures show Mr. Kroin signing in multiple capacities.
This is a disclosure of ownership structure and shared authority; it does not by itself indicate a change in board composition or corporate control.
Key Figures
Shares beneficially owned:4,062,500 sharesPercent of class:6.21%Shares outstanding:65,467,187 shares+2 more
5 metrics
Shares beneficially owned4,062,500 sharesOwnership reported as of March 31, 2026
Percent of class6.21%Calculated using shares outstanding as of March 24, 2026
Shares outstanding65,467,187 sharesAs reported by issuer on Form 10-K; date March 24, 2026
Shared voting power4,062,500 sharesReported shared voting power amount
Shared dispositive power4,062,500 sharesReported shared dispositive power amount
"Amendment No. 1 and cover references to a Schedule 13G/A filing"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
shared dispositive powerregulatory
"Item 4 (iv) Shared power to dispose or to direct the disposition of: 4,062,500"
joint filing statementregulatory
"JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k)"
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Bicara Therapeutics Inc.
(Name of Issuer)
Common Stock, $0.0001 par value
(Title of Class of Securities)
055477103
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
055477103
1
Names of Reporting Persons
Deep Track Capital, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,062,500.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,062,500.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,062,500.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.21 %
12
Type of Reporting Person (See Instructions)
IA, OO
SCHEDULE 13G
CUSIP Number(s):
055477103
1
Names of Reporting Persons
Deep Track Biotechnology Master Fund, Ltd.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,062,500.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,062,500.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,062,500.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.21 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
055477103
1
Names of Reporting Persons
David Kroin
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,062,500.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,062,500.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,062,500.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.21 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Bicara Therapeutics Inc.
(b)
Address of issuer's principal executive offices:
116 Huntington Ave, Suite 703, Boston, MA 02116
Item 2.
(a)
Name of person filing:
(i) Deep Track Capital, LP
(ii) Deep Track Biotechnology Master Fund, Ltd.
(iii) David Kroin
(b)
Address or principal business office or, if none, residence:
(i) Delaware
(ii) Cayman Islands
(iii) United States
(d)
Title of class of securities:
Common Stock, $0.0001 par value
(e)
CUSIP No.:
055477103
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
4,062,500
(b)
Percent of class:
6.21%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
4,062,500
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
4,062,500
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Deep Track Capital, LP
Signature:
/s/ David Kroin
Name/Title:
David Kroin, Managing Member of the General Partner of the Investment Adviser
Date:
05/15/2026
Deep Track Biotechnology Master Fund, Ltd.
Signature:
/s/ David Kroin
Name/Title:
David Kroin, Director
Date:
05/15/2026
David Kroin
Signature:
/s/ David Kroin
Name/Title:
David Kroin
Date:
05/15/2026
Exhibit Information
Item 4: Information with respect to the Reporting Persons' ownership of the Ordinary Shares as of March 31, 2026, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person.
The amount beneficially owned by each Reporting Person is determined using 65,467,187 shares outstanding as of March 24, 2026, as reported by the issuer on its 10-K filed with the SEC on March 30, 2026.
JOINT FILING STATEMENT
PURSUANT TO RULE 13d-1(k)
The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.
Dated: May 15, 2026
Deep Track Capital, LP
By: /s/ David Kroin
David Kroin, Managing Member of the General Partner of the Investment Adviser
Deep Track Biotechnology Master Fund, Ltd.
By: /s/ David Kroin
David Kroin, Director
David Kroin
By: /s/ David Kroin
David Kroin
What stake does Deep Track report in Bicara Therapeutics (BCAX)?
Deep Track-related reporting persons report beneficial ownership of 4,062,500 shares, equal to 6.21% of Bicara's common stock. This percentage is calculated using 65,467,187 shares outstanding as of March 24, 2026 per the issuer's 10-K.
Which entities filed the Schedule 13G/A for BCAX?
The filing was made jointly by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin. Signatures show Mr. Kroin signing on behalf of the fund entities in multiple capacities on May 15, 2026.
How is voting and dispositive power reported for the 4,062,500 shares?
The filing reports 0 sole voting/dispositive power and 4,062,500 in shared voting and shared dispositive power. The position is therefore disclosed as jointly controlled rather than solely controlled by any single reporting person.
What outstanding share count does the Schedule 13G/A use for percentage calculations?
The percentage (6.21%) is calculated using 65,467,187 shares outstanding as reported by the issuer on its Form 10-K filed March 30, 2026, with the outstanding count dated March 24, 2026.
Does the filing state whether the shares were acquired recently or how they will be traded?
The excerpt provides ownership as of March 31, 2026 and cites the outstanding share count; it does not state acquisition dates, trading intentions, or planned dispositions. Further amendments would be required to disclose changes in position.
